A randomized, double-blind, placebo controlled, section III medical demo evaluated the efficacy and safety profile of adalimumab as a monotherapy in clients with RA who had failed to respond to csDMARDs [191]. The outcomes showed both of those statistically significant improvement from the illness action and a great safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/